Vaccine News and Research

Latest Vaccine News and Research

New drug to stop cancer cells from growing and to stimulate immune system to destroy cancer cells found

A study conducted at Scott & White Healthcare in Temple, Texas, found that a new drug stopped the growth of breast tumors in mice. This drug is unique in that it works both by stopping the cancer cells from growing and metastasizing to other organs, and by stimulating the immune system to destroy breast cancer cells and keeps them from coming back.

23 Dec 2009

Macomb County Health Department announces 2009 H1N1 influenza vaccination program

The last large H1N1 influenza vaccination clinic for the 2009 flu season has been scheduled by the Macomb County Health Department. It is free of charge and will take place next Monday, Dec. 28, at Bethesda Christian Church in Sterling Heights from 10 a.m. to 3 p.m. Everyone over 6 months of age can receive the vaccine at this clinic.

23 Dec 2009

H1N1 flu vaccination clinics to be offered at 33 locations across Pennsylvania

The Department of Health will offer H1N1 flu vaccination clinics at 33 locations across Pennsylvania on Jan. 8 and 9, and anyone wishing to receive the vaccine is urged to make an appointment to attend.

22 Dec 2009

LA BioMed physician-researchers named Super Doctors in the Los Angeles Magazine

Los Angeles Magazine, in its January issue, will name 37 of the physician-researchers at Los Angeles Biomedical Research Institute (LA BioMed) to be among Southern California Super Doctors.

22 Dec 2009

Former CDC head to lead Merck's vaccine division

The pharmaceutical company Merck on Monday named former CDC head Julie Gerberding as president of the company's vaccine division, Reuters reports. "Gerberding, who led the CDC from 2002 to 2009 and stepped down when President Barack Obama took office, will head up the company's $5 billion global vaccine business that includes shots to prevent chickenpox, cervical cancer and pneumonia," the news service reports.

22 Dec 2009

Health Canada approves Prevnar 13 vaccine for invasive pneumococcal disease

Following a Priority Review, Health Canada has approved Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein)) for children aged six weeks through five years for active immunization against invasive pneumococcal disease, a bacterial infection that can include meningitis (inflammation of the coverings of the brain and spinal cord), sepsis (bloodstream infection), bacteremic pneumonia, pleural empyema (accumulation of pus in the cavity surrounding the lungs) and bacteremia (bacteria in the blood).

22 Dec 2009

3rd Annual OneMedForum to highlight therapeutic and diagnostic products for cancers

ProActive Capital Resources Group, a company dedicated to the discovery and creation of value in the small and micro-cap marketplace, is proud to announce client presentations at the 3rd Annual OneMedForum held in San Francisco, January 12-13, 2010. ProActive clients presenting are: Access Pharmaceuticals, ImmunoCellular Therapeutics, DataTrak International, Quantum Immunologics, with Protox Therapeutic's presentation pending.

22 Dec 2009

Sinovac Biotech selected as Top 10 most competitive companies for 2009

Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, announced today that Sinovac was selected by China Business Media as one of China's Top 10 most competitive companies listed overseas for 2009.

22 Dec 2009

New quantities of H1N1 vaccine available for walk-in patients; no appointments necessary

U.S. HealthWorks Medical Group, a leading operator of occupational health and urgent care centers in the nation, today announced that most of its 128 medical centers have new quantities of H1N1 vaccine available for walk-in patients – no appointments necessary.

22 Dec 2009

Study results of CSL’s pandemic H1N1 2009 vaccine published in JAMA

CSL Limited, Australia’s leading biopharmaceutical company, announced the Journal of the American Medical Association (JAMA) has published data from a clinical trial conducted in Australia to study CSL’s pandemic H1N1 2009 ‘swine’ flu vaccine.

22 Dec 2009

Duane Reade offers H1N1 vaccines for New York residents

Duane Reade, the largest drug store chain in New York City, today announced that H1N1 vaccines are now available. As previously announced, Duane Reade pharmacies are providing New Yorkers with the H1N1 vaccine as part of the Company's commitment to servicing the health and wellness needs of the City's residents.

22 Dec 2009

NMA urges parents to protect their children from meningococcal disease

This winter, while many parents are focused on influenza prevention, the National Meningitis Association (NMA) is urging parents to also protect their families from meningococcal disease, a deadly but potentially vaccine preventable bacterial infection.

22 Dec 2009

Select CVS/pharmacy locations and all MinuteClinic medical clinics offer H1N1 vaccinations

Select CVS/pharmacy locations and all MinuteClinic medical clinics throughout Arizona are now offering H1N1 vaccinations. H1N1 vaccine is now also available at select MinuteClinic locations in Illinois in the Chicago area and in Nevada in the Las Vegas area on demand seven days a week with no appointment necessary.

22 Dec 2009

SafeMinds disappointed with CDC's report on autism spectrum disorders

A study released Friday by the Centers for Disease Control (CDC) reported that autism prevalence has increased a staggering 57% from the 1994 rate of 1 in 150 to 1 in 110 for children born in 1996. SafeMinds is extremely dissatisfied with CDC's lack of commitment to researching environmental causes and the timing of their announcement.

22 Dec 2009

New findings reveal POPG lipid can prevent RSV infection in lungs

Researchers at National Jewish Health have discovered that a naturally occurring lipid in the lung can prevent RSV infection and inhibit spread of the virus after an infection is established. RSV is the major cause of hospitalization for children in the first two years of life, and is increasingly recognized as a dangerous pathogen in adults with chronic lung diseases, the elderly, and immunocompromised individuals. Currently, there is no effective vaccine for the virus.

22 Dec 2009

Findings may help develop new antiviral drugs for influenza

Investigators at Burnham Institute for Medical Research (Burnham), Mount Sinai School of Medicine (Mount Sinai), the Salk Institute for Biological Studies (Salk) and the Genomics Institute of the Novartis Research Foundation (GNF) have identified 295 human cell factors that influenza A strains must harness to infect a cell, including the currently circulating swine-origin H1N1.

22 Dec 2009

One dose of vaccine may be effective to protect infants and children from H1N1 virus, shows study

One dose of vaccine may be effective to protect infants and children and reduce transmission of the H1N1 virus, according to a study in JAMA, published online today because of its public health implications. The study will appear in the January 6 print edition of the journal.

21 Dec 2009

Positive interim results from Idera Pharmaceuticals' IMO-2125 Phase 1 clinical trial for HCV

Idera Pharmaceuticals, Inc. today announced positive interim results from a Phase 1 clinical trial of IMO-2125 in patients with chronic hepatitis C virus infection (HCV). IMO-2125 is an agonist of Toll-like Receptor 9 that Idera designed to treat HCV by inducing endogenous interferon-alpha and other Th1-type cytokines and chemokines.

21 Dec 2009

Positive interim results from Medicago's H5N1 vaccine Phase I human clinical trial

Medicago Inc. a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today reported positive interim results from a Phase I human clinical trial with its H5N1 Avian Influenza vaccine candidate ("H5N1 vaccine"). The vaccine was found to be safe, well tolerated and also induced a solid immune response.

21 Dec 2009

Soligenix commences SGX201 Phase 1/2 clinical trial for acute radiation enteritis prevention

Soligenix, Inc., formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today that it has initiated a Phase 1/2 clinical trial evaluating SGX201, a time-release formulation of oral beclomethasone 17,21-dipropionate (oral BDP), for the prevention of acute radiation enteritis.

21 Dec 2009

Vaccine News and Research

Latest Vaccine News and Research

New drug to stop cancer cells from growing and to stimulate immune system to destroy cancer cells found

Macomb County Health Department announces 2009 H1N1 influenza vaccination program

H1N1 flu vaccination clinics to be offered at 33 locations across Pennsylvania

LA BioMed physician-researchers named Super Doctors in the Los Angeles Magazine

Former CDC head to lead Merck's vaccine division

Health Canada approves Prevnar 13 vaccine for invasive pneumococcal disease

3rd Annual OneMedForum to highlight therapeutic and diagnostic products for cancers

Sinovac Biotech selected as Top 10 most competitive companies for 2009

New quantities of H1N1 vaccine available for walk-in patients; no appointments necessary

Study results of CSL’s pandemic H1N1 2009 vaccine published in JAMA

Duane Reade offers H1N1 vaccines for New York residents

NMA urges parents to protect their children from meningococcal disease

Select CVS/pharmacy locations and all MinuteClinic medical clinics offer H1N1 vaccinations

SafeMinds disappointed with CDC's report on autism spectrum disorders

New findings reveal POPG lipid can prevent RSV infection in lungs

Findings may help develop new antiviral drugs for influenza

One dose of vaccine may be effective to protect infants and children from H1N1 virus, shows study

Positive interim results from Idera Pharmaceuticals' IMO-2125 Phase 1 clinical trial for HCV

Positive interim results from Medicago's H5N1 vaccine Phase I human clinical trial

Soligenix commences SGX201 Phase 1/2 clinical trial for acute radiation enteritis prevention

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Vaccine News and Research

Latest Vaccine News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in